Castle Biosciences (CSTL) Current Assets (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Current Assets data on file, last reported at $328.9 million in Q1 2026.

• Quarterly Current Assets fell 5.86% year-over-year to $328.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $328.9 million (down 5.86% YoY) and the FY2025 annual result came in at $361.1 million, changed 0.26% from the prior year.
• Current Assets fell to $328.9 million in Q1 2026 per CSTL's latest filing, from $361.1 million in the prior quarter.
• The five-year high for Current Assets was $361.1 million in Q4 2025, with the low at $269.1 million in Q2 2023.
• Average Current Assets over 5 years is $318.5 million, with a median of $320.4 million recorded in 2024.
• Year-over-year, Current Assets fell 23.15% in 2022 and gained 23.3% in 2024.
• Castle Biosciences' Current Assets stood at $292.3 million in 2022, then gained by 1.15% to $295.6 million in 2023, then advanced by 21.82% to $360.2 million in 2024, then grew by 0.26% to $361.1 million in 2025, then retreated by 8.92% to $328.9 million in 2026.
• Business Quant data shows CSTL's Current Assets at $328.9 million in Q1 2026, $361.1 million in Q4 2025, and $357.6 million in Q3 2025.